-
2024-515146-16-00
5
2023-05-15
Colorectal surgery
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2024-513248-27-00
5
2020-07-20
Patients, men or women over 18 old, with inoperable vertebral bone met
-
2024-514094-22-00
5
2019-01-18
Intrecerebral Haemorrhage
-
2024-518553-41-00
5
2024-11-08
colon cancer and rectal with liver metastasis
-
2023-504753-12-00
5
2024-10-01
Lung Cancer, Non-Small Cell
-
2024-513530-37-00
5
2024-08-09
Delirium
-
2023-505972-32-00
5
2024-02-26
locally advanced anal squamous cell carcinoma
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2024-512224-11-00
4
2023-03-24
Histologically confirmed frail Limited Disease Small Cell Lung Cancer
-
2023-503999-24-00
5
2022-06-01
Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2024-513005-31-00
5
2020-06-11
Patients with untreated metastatic Estrogen Receptor positive (ER+), H
-
2024-514829-36-00
5
2019-12-02
High-risk biochemically-relapsed prostate adenocarcinoma following rad
-
2024-510776-20-00
5
2019-10-25
Female or male patients with histologically confirmed HR-positive, HER
-
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
-
2024-515946-17-00
5
2019-07-22
Non Small Cell Lung Cancer
-
2024-512165-13-00
4
2019-05-13
Localised unresectable adenocarcinoma or squamous cell carcinoma of th
-
2024-513207-13-00
4
2019-03-21
oligometastatic hormone sensitive prostate cancer
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
-
2024-513964-24-00
5
2017-09-14
Squamous cell carcinoma, previously untreated
Stage III, stage IVa (op
-
2024-517489-41-00
5
2017-03-27
High-risk stage III colon cancer
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer